U.S. License Holder:
Sanofi Aventis US
Date of License:
SARCLISA (isatuximab-irfc) is a CD38-directed cytolytic antibody indicated:
In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor;
In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.